Studies why people with obesity regain weight after a behavioral weight loss program
Studies adults with obesity who regain weight after a behavioral weight loss program.
Key facts
- Who runs it
- University of Pittsburgh
- Where
- New York and Philadelphia, United StatesSee the 3 sites
- Trial code
- Registry title
- A Study to Investigate Why Overweight People Regain Weight After Losing Weight in a Behavioral Weight Loss Program
- Status
- Recruiting
- People taking part
- 205 people, planned
- Started
- 29 Sept 2023
- Expected to end
- Mar 2027
- Type of study
- Interventional
- Treatments tested
- Weight loss
- Record updated
- 12 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 25 to 59 with obesity who have kept a steady weight. They join a behavioral weight loss program and are followed for 1 year to see who regains weight.
- Age
- 25 to under 60 years
- Sex
- All sexes
- Disease stage
- BMI 30 to under 40 kg/m2 at the first screening visit.
- Earlier treatment
- Weight within 5% of current weight for the past 6 months. Cannot be in a supervised weight reduction program. Cannot have had bariatric surgery, endoscopic therapy, device-based therapy for obesity, liposuction, cryolipolysis, or abdominoplasty.
Main reasons for not taking part
- Diabetes (type 1 or 2) or taking a glucose lowering medication
- Cardiovascular disease within the past 6 months
- Current major depressive disorder, or one within the past 2 years
- Eating disorder: anorexia nervosa, bulimia nervosa or binge eating disorder
- Currently pregnant, less than one year after giving birth, or planning pregnancy within 2 years
The registry criteria, word for word
Show all 46 criteriaShow less
Who can take part
- Age: 25 - <60 years
- BMI: 30 - <40 kg/m2 at the first screening visit
- Within 5% of current weight, for the past 6 months at the first screening visit
- Able to participate in ergometry testing
- Has a smart phone, tablet or computer with access to the internet
Who cannot take part
- Known or suspected abuse or misuse of alcohol, prescription drugs, or recreational drugs
- Regularly taking medication or supplement known to affect appetite, energy expenditure, or weight (e.g. appetite suppressants, steroids-including inhaled steroids but not topical, alpha-blockers, beta-blockers, certain psychotropic medications)
- Currently taking anticoagulant medication
- Prior or planned bariatric surgery, endoscopic therapy, device-based therapy for obesity, liposuction, cryolipolysis, or abdominoplasty
- Metal implants, piercings that cannot be removed, or metal-based tattoos or hair treatments
- Inability to achieve weight stability (defined in section 4.2.1) during the 2 weeks prior to initiation of the baseline Doubly Labeled Water (DLW) assessment
- History of pulmonary embolus in the past 6 months
- Cardiovascular disease (e.g. myocardial infarction, stroke, hospitalization for unstable angina, or transient ischemic attack) within the past 6 months
- Current major depressive disorder or history of major depressive disorder within 2 years
- Presently classified as being in New York Heart Association Class II or greater or dysrhythmia
- Thyroid disease requiring hormones or medication or TSH < 0.5 or > 5 mIU/L
- Renal disease requiring dialysis
- Known HIV infection
- Active cancer or current chemotherapy treatment, or history of cancer requiring treatment in the past 5 years except for non-melanoma skin cancers or cancers that have clearly been cured
- Current or past history of anorexia nervosa or bulimia nervosa
- Current or past diagnosis of binge eating disorder
- Diagnosis of other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder)
- Antiretroviral therapy (ART), including treatment for HIV, pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP) within the past 3 months
- Current celiac or diagnosed gluten intolerance or inflammatory bowel disease requiring specialized diet
- Known severe allergy (e.g. anaphylaxis) to nuts or other foods
- Systolic blood pressure (BP) >160 mmHg and/or diastolic BP >100 mmHg on at least 2 measurements during the clinical screening visit or resting heart rate < 45 beats per minute or >100 on 2 measurements during the clinical screening visit
- Known allergy to lidocaine or acetaminophen
- Diabetes (type 1 or 2 - HbA1c ≥ 6.5%, fasting glucose ≥ 126 mg/dL) or currently taking a glucose lowering medication
- ALT or AST greater than 5 times the upper limit of normal or active gall bladder disease
- Significant anemia (Hgb < 10 g/dL) or thrombocytopenia (platelet count < 60,000 /mm3)
- Leukopenia defined as:; Males: WBC < 3,100 /mm3 or (WBC 3,100 - < 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result) Females: WBC < 3,400 /mm3 or (WBC 3,400 - < 4,000 /mm3 and at least 1 Duffy antigen (A, B) positive or no result)
- Blood clotting disorder or INR > ULN or PT > ULN or (a)PTT > ULN
- If 25-29 years old, > 5% deviation from maximum weight (excluding weights while pregnant) since age 25 years
- If at least 30 years old, > 5% deviation from maximum weight (excluding weights while pregnant) in last 5 years or ≥ 10% deviation from maximum weight (excluding weights while pregnant) since age 30 years
- Any regular tobacco or nicotine use in the past year
- Currently engaging in intense physical training or training for a sports event including, but not limited to, a marathon or body building
- Currently pregnant, or less than one-year post-partum or actively planning to become pregnant within the next two years
- Unwillingness to abstain from marijuana/cannabis use for 3 weeks at each of the four assessment time points
- Currently enrolled in a supervised weight reduction program
- Severely restricted diets: Vegan (no meat, fish, dairy, eggs, or honey), very low carbohydrate (<15% calorie as carbohydrate), very low fat (<15% calories as fat), or strictly gluten free
- Night or rotating shift worker
- Systolic blood pressure (BP) <90 mmHg and/or diastolic BP <60 mmHg on 2 measurements during the clinical screening visit
- Exceeds limitations to fit dual-energy X-ray absorptiometry (DXA) field of view
- Non-compliance with appointments or tasks (food diaries, etc.) during the screening phase
- Tendency to form thick or raised scars
- At high risk for suicide, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 59 years old?
Where in United States
- Columbia University Irving Medical CenterNew York, United StatesContact: Dympna Gallagher, EdDTaking people
- Drexel UniversityPhiladelphia, United StatesContact: Michael R Lowe, PhDTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Matthew Hayes, PhDTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to determine the physiological basis for the differences in weight regain among adults (25-59 years old) with obesity following participation in a behavioral weight loss program. Eligible participants will undergo a baseline evaluation after which they will enter an up to 20 week behavioral weight loss program with the goal of losing at least 7 percent of their baseline weight within 35 weeks. Participants who meet the weight loss goal will be asked to remain weight stable for 2 weeks after which they will undergo a clinical examination. They will then be observed for 1 year during which they will undergo 2 additional clinical examinations, one 4 months after completing the weight loss program, and the other 12 months after completing the weight loss program.
The group in the trial
- Weight lossOther group
A 37 week behavioral intervention aimed at decreasing energy intake and increasing physical activity.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Physiology of the Weight Reduced State
- Plain-language title
- Studies why people with obesity regain weight after a behavioral weight loss programGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05748158, who can take part
- Record updated
- 12 June 2026